Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective

Saved in:
Bibliographic Details
Published in:JAMA internal medicine Vol. 181; no. 10; p. 1276
Main Authors: Dunn, Billy, Stein, Peter, Cavazzoni, Patrizia
Format: Journal Article
Language:English
Published: United States 01.10.2021
Subjects:
Alzheimer Disease - diagnosis
Alzheimer Disease - drug therapy
Amyloid beta-Peptides - antagonists & inhibitors
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - economics
Brain - diagnostic imaging
Brain - pathology
Decision Making
Dose-Response Relationship, Drug
Drug Approval - methods
Humans
Infusions, Intravenous - methods
Magnetic Resonance Imaging - methods
Nootropic Agents - administration & dosage
Nootropic Agents - adverse effects
Nootropic Agents - economics
Plaque, Amyloid - diagnostic imaging
Positron-Emission Tomography - methods
Product Surveillance, Postmarketing
Randomized Controlled Trials as Topic - methods
Treatment Outcome
United States
United States
ISSN:2168-6114, 2168-6114
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2168-6114
2168-6114
DOI:10.1001/jamainternmed.2021.4607